Oculis’ (OCS) “Buy” Rating Reaffirmed at Chardan Capital

Chardan Capital reissued their buy rating on shares of Oculis (NASDAQ:OCS) in a report released on Thursday morning,Benzinga reports. The firm currently has a $28.00 price target on the stock.

Separately, HC Wainwright decreased their price objective on shares of Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a research note on Thursday.

Oculis Price Performance

Shares of OCS stock opened at $18.70 on Thursday. The stock’s fifty day simple moving average is $20.86 and its 200 day simple moving average is $16.88. Oculis has a one year low of $10.55 and a one year high of $23.08. The firm has a market cap of $757.42 million, a price-to-earnings ratio of -9.69 and a beta of 0.02. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.02 and a quick ratio of 4.02.

Oculis (NASDAQ:OCS) last issued its earnings results on Tuesday, March 11th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.28). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. On average, analysts expect that Oculis will post -2.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in OCS. Bellevue Group AG acquired a new stake in Oculis in the 4th quarter valued at about $170,000. XTX Topco Ltd bought a new stake in shares of Oculis during the fourth quarter valued at approximately $225,000. Geode Capital Management LLC increased its holdings in shares of Oculis by 12.0% in the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock valued at $284,000 after purchasing an additional 1,800 shares in the last quarter. Citadel Advisors LLC bought a new position in Oculis in the 4th quarter worth approximately $389,000. Finally, Bank of America Corp DE lifted its holdings in Oculis by 58.2% during the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock worth $493,000 after buying an additional 10,667 shares in the last quarter. 22.30% of the stock is owned by institutional investors.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.